- Home
- Equipment
- netherlands
- immunotherapeutic
Show results for
Refine by
Immunotherapeutic Equipment Supplied In Netherlands
12 equipment items found
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK003: A phase 1 study evaluating NK cells as a treatment for patients with relapse and refractory acute myeloid leukemia (AML). This study was designed based on promising clinical proof-of-concept data from two studies, one at MD Anderson Cancer Center and one at HCPA in ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK00X: Kiadis is evaluating preclinical programs with K-NK-cell therapies for the treatment of hematologic and solid ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK002: A phase 2 clinical study evaluating haplo-identical NK cells to prevent post-transplant relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This study was designed based on promising clinical proof-of-concept data from MD Anderson Cancer Center. The phase 2 trial for K-NK002 will be conducted in collaboration with the Bone Marrow Transplant Clinical ...
Manufactured by:HAL Allergy Group based inLeiden, NETHERLANDS
HAL Allergy offers allergen drops that can be administered by applying a few drops under the tongue (sublingual immunotherapy). Sublingual products are manufactured from standardized allergen extracts formulated in glycerol. Glycerol improves the dosing of the product by enhancing the stickiness in the mouth, and is a stabilizer of the allergen ...
Manufactured by:HAL Allergy Group based inLeiden, NETHERLANDS
Our wasp and bee venom SCIT product is an immunotherapy designed for people with an allergy to wasp or bee stings. Its effect is brought about by administering increasing amounts of the ...
Manufactured by:HAL Allergy Group based inLeiden, NETHERLANDS
Our allergoid SCIT product is available for most prevalent allergens such as grasses, trees and mites. It is a modern form of therapy involving specific modified allergens. The advantage of this form of treatment is enhanced safety (by means of significantly reduced allergenicity), combined with a high level of efficacy. The benefit is a simple and patient-friendly ...
Manufactured by:HAL Allergy Group based inLeiden, NETHERLANDS
Our sublingual (SLIT) product is a high-dose treatment with proven long-term efficacy. With an administration of a few drops under the tongue, the patient can carry out the treatment at home and it allows for an individually tailored treatment. Sublingual immunotherapy is available for a wide range of respiratory allergens. The therapy is specifically designed to target the allergen or ...
Manufactured by:HAL Allergy Group based inLeiden, NETHERLANDS
Subcutaneous immunotherapy (SCIT) available for major respiratory and venom allergens. Our subcutaneous (SCIT) allergoid product is designed for a faster, simpler and more effective immunotherapy to improve the patient’s convenience for the treatment of a wide range of allergic symptoms, from allergic conjunctivitis and allergic rhinitis to allergic asthma. ...
Manufactured by:Citeq Biologics based inGroningen, NETHERLANDS
A freeze-dried extract of peanut. Vials of 10 or 100 milligram. We produce large batches and deliver ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
Ushering in the Future of NK-cell Therapy: Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years has significant progress been made in understanding the complexities and therapeutic potential these cells offer in helping fight cancer and other diseases.1 Today, we ...
Manufactured by:ViciniVax BV based inGroningen, NETHERLANDS
Our first product candidate Vvax001, a therapeutic cancer vaccine against (pre)malignant cervical lesions, is currently in clinical development. We outsource process development and GMP manufacturing to experienced CMO’s, leading to a first clinical trial, which has been started in ...